Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: Final 5-year report of the LEADERS (limus eluted from a durable versus erodable stent coating) randomized, noninferiority trial
Patrick W. Serruys,Vasim Farooq,Bindu Kalesan,Ton de Vries,Paweł Buszman,Axel Linke,Thomas Ischinger,Volker Klauss,Franz R. Eberli,William Wijns,Marie Claude Morice,Carlo Di Mario,Roberto Corti,Diethmar Antoni,Hae Y. Sohn,Pedro Eerdmans,Tessa Rademaker-Havinga,Gerrit-Anne van Es,Bernhard Meier,Peter Jüni,Stephan Windecker +20 more
Reads0
Chats0
TLDR
The safety benefit of the biodegradable polymer BES, compared with the durable polymer SES, was related to a significant reduction in very late ST (>1 year) and associated composite clinical outcomes.Abstract:
Objectives This study sought to report the final 5 years follow-up of the landmark LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) trial. Background The LEADERS trial is the first randomized study to evaluate biodegradable polymer–based drug-eluting stents (DES) against durable polymer DES. Methods The LEADERS trial was a 10-center, assessor-blind, noninferiority, “all-comers” trial (N = 1,707). All patients were centrally randomized to treatment with either biodegradable polymer biolimus-eluting stents (BES) (n = 857) or durable polymer sirolimus-eluting stents (SES) (n = 850). The primary endpoint was a composite of cardiac death, myocardial infarction (MI), or clinically indicated target vessel revascularization within 9 months. Secondary endpoints included extending the primary endpoint to 5 years and stent thrombosis (ST) (Academic Research Consortium definition). Analysis was by intention to treat. Results At 5 years, the BES was noninferior to SES for the primary endpoint (186 [22.3%] vs. 216 [26.1%], rate ratio [RR]: 0.83 [95% confidence interval (CI): 0.68 to 1.02], p for noninferiority Conclusions The safety benefit of the biodegradable polymer BES, compared with the durable polymer SES, was related to a significant reduction in very late ST (>1 year) and associated composite clinical outcomes. (Limus Eluted From A Durable Versus ERodable Stent Coating [LEADERS] trial; NCT00389220 )read more
Citations
More filters
Journal ArticleDOI
Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial.
Timo H. Mäkikallio,Niels Ramsing Holm,Mitchell Lindsay,Mark S. Spence,Andrejs Erglis,Ian B. A. Menown,Thor Trovik,Markku Eskola,Hannu Romppanen,Thomas Kellerth,Jan Ravkilde,Lisette Okkels Jensen,Gintaras Kalinauskas,Rikard Linder,Markku O. Pentikäinen,Anders Hervold,Adrian P. Banning,Azfar Zaman,Jamen Cotton,Erlend Eriksen,Sulev Margus,Henrik Toft Sørensen,Henrik Toft Sørensen,Per Hostrup Nielsen,Matti Niemelä,Kari Kervinen,Jens Flensted Lassen,Michael Maeng,Keith G. Oldroyd,Geoff Berg,Simon J Walsh,Colm G. Hanratty,Indulis Kumsars,Peteris Stradins,Terje K. Steigen,Ole Fröbert,Alastair N J Graham,Petter C Endresen,Matthias Corbascio,Olli A. Kajander,Uday Trivedi,Juha Hartikainen,Vesa Anttila,David Hildick-Smith,Leif Thuesen,Evald Høj Christiansen +45 more
TL;DR: In this article, the authors compared percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) for the treatment of left main coronary artery disease.
Journal ArticleDOI
Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
Antonio Colombo,Alaide Chieffo,A. Frasheri,Roberto Garbo,Monica Masotti-Centol,Neus Salvatella,Juan Francisco Oteo Dominguez,Luigi Steffanon,Giuseppe Tarantini,Patrizia Presbitero,Alberto Menozzi,Edoardo Pucci,Josepa Mauri,Bruno Mario Cesana,Gennaro Giustino,Gennaro Sardella +15 more
TL;DR: In a low-risk population, the noninferiority hypothesis of 6 vs. 12 months DAPT following second-generation DES implantation appears accepted for the incidence of cardiac death, MI, stroke, definite/probable stent thrombosis, and BARC type 3 or 5 bleeding at 12 months.
Journal ArticleDOI
Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease: Consensus Definitions From Peripheral Academic Research Consortium (PARC)
Manesh R. Patel,Michael S. Conte,Donald E. Cutlip,Nabil Dib,Patrick J. Geraghty,William A. Gray,William R. Hiatt,Mami Ho,Koji Ikeda,Fumiaki Ikeno,Michael R. Jaff,W. Schuyler Jones,Masayuki Kawahara,Robert A. Lookstein,Roxana Mehran,Sanjay Misra,Lars Norgren,Jeffrey W. Olin,Thomas J. Povsic,Kenneth Rosenfield,John H. Rundback,Fadi Shamoun,James E. Tcheng,Thomas T. Tsai,Yuka Suzuki,Pascal Vranckx,Bret N. Wiechmann,Christopher J. White,Hiroyoshi Yokoi,Mitchell W. Krucoff +29 more
TL;DR: These consensus definitions include the clinical presentation, anatomic depiction, interventional outcomes, surrogate imaging and physiological follow-up, and clinical outcomes of patients with lower-extremity peripheral artery disease that should result in more efficient regulatory evaluation and best practice guidelines to inform clinical decisions.
Journal Article
Incomplete Stent Apposition and Very Late Stent Thrombosis After Drug-Eluting Stent Implantation
StéphaneCook,PeterWenaweser,MarioTogni,MichaelBillinger,CyrillMorger,ChristianSeiler,RolfVogel,OttoHess,BernhardMeier,StephanWindecker +9 more
TL;DR: Investigating differences of the stented segment between patients with and without very late stent thrombosis with the use of intravascular ultrasound found differences had longer lesions and stents per lesion than with control patients.
Journal ArticleDOI
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis
Eliano Pio Navarese,Kenneth Tandjung,Bimmer E. Claessen,Felicita Andreotti,Mariusz Kowalewski,David E. Kandzari,Dean J. Kereiakes,Ron Waksman,Laura Mauri,Ian T Meredith,Aloke V. Finn,Hyo-Soo Kim,Jacek Kubica,Harry Suryapranata,Toni M. Aprami,Giuseppe Di Pasquale,Clemens von Birgelen,Elvin Kedhi +17 more
TL;DR: All investigated DES were similar with regards to efficacy endpoints, except for Endeavor zotarolimus-ES and paclitaxel-ES, which were associated with significantly increased the odds of target lesion and target vessel revascularisations compared with other devices.
References
More filters
Journal ArticleDOI
Clinical End Points in Coronary Stent Trials A Case for Standardized Definitions
Donald E. Cutlip,Stephan Windecker,Roxana Mehran,Ashley B Boam,David J. Cohen,Gerrit-Anne van Es,P. Gabriel Steg,Marie-Angèle Morel,Laura Mauri,Pascal Vranckx,Eugene P. McFadden,Alexandra J. Lansky,Martial Hamon,Mitchell W. Krucoff,Patrick W. Serruys +14 more
TL;DR: Criteria for assessment of death, myocardial infarction, repeat revascularization, and stent thrombosis were developed and provide consistency across studies that can facilitate the evaluation of safety and effectiveness of these devices.
Journal ArticleDOI
Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease
Patrick W. Serruys,Marie-Claude Morice,A. Pieter Kappetein,Antonio Colombo,David R. Holmes,Michael J. Mack,Elisabeth Ståhle,Ted Feldman,Marcel van den Brand,Eric Bass,Nic Van Dyck,Katrin Leadley,Keith D. Dawkins,Friedrich W. Mohr,Boston Scientif +14 more
TL;DR: CABG remains the standard of care for patients with three-vessel or left main coronary artery disease, since the use of CABG, as compared with PCI, resulted in lower rates of the combined end point of major adverse cardiac or cerebrovascular events at 1 year.
Journal ArticleDOI
Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)
William Wijns,Philippe Kolh,Nicolas Danchin,Volkmar Falk,Stefan James,Miodrag Ostojic,Massimo F. Piepoli,Charles Pirlet,José L. Pomar,Flavio Ribichini,Martin J. Schalij,Paul Sergeant,Patrick W. Serruys,Sigmund Silber,David P. Taggart +14 more
TL;DR: Guidelines and Expert Consensus Documents summarize and evaluate all available evidence to assist physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome and the risk–benefit ratio of diagnostic or therapeutic means.
Journal ArticleDOI
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
Glenn N. Levine,Eric R. Bates,James C. Blankenship,Steven R. Bailey,John A. Bittl,Bojan Cercek,Charles E. Chambers,Stephen G. Ellis,Robert A. Guyton,Steven M. Hollenberg,Umesh N. Khot,Richard A. Lange,Laura Mauri,Roxana Mehran,Issam Moussa,Debabrata Mukherjee,Brahmajee K. Nallamothu,Henry H. Ting,Alice K. Jacobs,Nancy M. Albert,Mark A. Creager,Steven M. Ettinger,Jonathan L. Halperin,Judith S. Hochman,Frederick G. Kushner,E. Magnus Ohman,William G. Stevenson,Clyde W. Yancy +27 more
TL;DR: Alice K. Jacobs, MD, FACC, FAHA, Chair Jeffrey L. Anderson, PhD, CCNS, CCRN, FAH, Chair-Elect - The first female FACC-FAHA board member to be elected in the history of the sport.
Journal ArticleDOI
Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk
Michael Joner,Aloke V. Finn,Andrew Farb,Erik Mont,Frank D. Kolodgie,Elena Ladich,Robert Kutys,Kristi Skorija,Herman K. Gold,Renu Virmani +9 more
TL;DR: The Cypher and Taxus DES result in delayed arterial healing when compared with BMS of similar implant duration, and the cause of DES LST is multifactorial with delayed healing in combination with other clinical and procedural risk factors playing a role.
Related Papers (5)
Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial
Stephan Windecker,Patrick W. Serruys,Simon Wandel,Paweł Buszman,Stanislaw Trznadel,Axel Linke,Karsten Lenk,Thomas Ischinger,Volker Klauss,Franz R. Eberli,Roberto Corti,William Wijns,Marie-Claude Morice,Carlo Di Mario,Simon J. Davies,Robert-Jan van Geuns,Pedro Eerdmans,Gerrit Anne van Es,B. Meier,Peter Jüni +19 more
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis
Tullio Palmerini,Giuseppe Biondi-Zoccai,Diego Della Riva,Christoph Stettler,Diego Sangiorgi,Fabrizio D'Ascenzo,Takeshi Kimura,Carlo Briguori,Manel Sabaté,Hyo-Soo Kim,Antoinette de Waha,Elvin Kedhi,Pieter C. Smits,Christoph Kaiser,Gennaro Sardella,Antonino G.M. Marullo,Ajay J. Kirtane,Martin B. Leon,Gregg W. Stone +18 more